When does Gerresheimer (GXI.DE) report earnings?

Gerresheimer’s earnings are scheduled for 19 March 2026. Expect updates on revenue, adjusted EBIT margin, free cash flow, and management commentary on working capital and net debt.

What price target does Meyka AI give for GXI.DE stock?

Meyka AI’s model shows a 12-month base-case target of **€24.00**, a bear case **€14.00**, and a bull case **€33.00**. These are projections, not guarantees.

What are the main risks for GXI.DE stock after earnings?

Top risks include weak free cash flow, higher-than-expected capex, elevated net debt to EBITDA **5.48x**, and slower demand in key pharma packaging segments. Guidance on those items will drive near-term moves.

How does valuation compare with the Healthcare sector?

GXI.DE trades at a PE of **28.44**, close to the Healthcare sector average PE **29.52**, but it carries higher leverage and lower margins, which raises relative risk versus peers.

DE Stocks

GXI.DE Gerresheimer AG XETRA pre-market €19.34 18 Mar 2026: earnings set to guide

ByDanny Kontos March 18, 2026March 18, 2026

We see GXI.DE stock trading at €19.34 pre-market on XETRA as Gerresheimer AG heads into its earnings release for 19 March 2026. The print will spotlight margins, working capital trends and cash flow after a sharp YTD decline of -30.43%. Investors will watch EPS of €0.68 and guidance for free cash flow while the market weighs high leverage and a PE of 28.44 against sector peers in Healthcare. We summarise what to expect, how the report ties to price, and key scenarios for traders and longer-term investors.